TW200510413A - Novel pyrrolodihydroisoquinolines - Google Patents

Novel pyrrolodihydroisoquinolines

Info

Publication number
TW200510413A
TW200510413A TW093119579A TW93119579A TW200510413A TW 200510413 A TW200510413 A TW 200510413A TW 093119579 A TW093119579 A TW 093119579A TW 93119579 A TW93119579 A TW 93119579A TW 200510413 A TW200510413 A TW 200510413A
Authority
TW
Taiwan
Prior art keywords
novel
pyrrolodihydroisoquinolines
inducers
hyper
apoptosis
Prior art date
Application number
TW093119579A
Other languages
English (en)
Inventor
Matthias Vennemann
Thomas Bar
Jurgen Braunger
Petra Gimmnich
Paola Ciapetti
Jean-Marie Contreras
Camille Georges Wermuth
Volker Gekeler
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of TW200510413A publication Critical patent/TW200510413A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW093119579A 2003-06-30 2004-06-30 Novel pyrrolodihydroisoquinolines TW200510413A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03014424 2003-06-30

Publications (1)

Publication Number Publication Date
TW200510413A true TW200510413A (en) 2005-03-16

Family

ID=33560746

Family Applications (2)

Application Number Title Priority Date Filing Date
TW093119589A TW200510407A (en) 2003-06-30 2004-06-30 Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors
TW093119579A TW200510413A (en) 2003-06-30 2004-06-30 Novel pyrrolodihydroisoquinolines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW093119589A TW200510407A (en) 2003-06-30 2004-06-30 Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors

Country Status (22)

Country Link
US (2) US20060148838A1 (zh)
EP (2) EP1641794A1 (zh)
JP (2) JP2009513495A (zh)
KR (1) KR20060030483A (zh)
CN (2) CN1809564A (zh)
AR (2) AR044956A1 (zh)
AT (1) ATE478868T1 (zh)
AU (2) AU2004253690B2 (zh)
BR (1) BRPI0411897A (zh)
CA (2) CA2530316A1 (zh)
DE (1) DE602004028827D1 (zh)
EA (1) EA012110B1 (zh)
IL (1) IL171997A0 (zh)
IS (1) IS8238A (zh)
MX (2) MXPA05013822A (zh)
NO (1) NO20060202L (zh)
NZ (1) NZ544591A (zh)
RS (2) RS20050946A (zh)
TW (2) TW200510407A (zh)
UA (1) UA86591C2 (zh)
WO (2) WO2005003129A1 (zh)
ZA (2) ZA200509265B (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003129A1 (en) * 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolodihydroisoquinolines as pde10 inhibitors
WO2006089815A1 (en) * 2005-01-12 2006-08-31 Nycomed Gmbh Novel pyrrolodihydroisoquinolines as pde10 inhibitors
JP2008526817A (ja) * 2005-01-12 2008-07-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のピロロジヒドロイソキノリン
WO2008028914A1 (en) 2006-09-07 2008-03-13 Nycomed Gmbh Combination treatment for diabetes mellitus
EP2152663B1 (en) 2007-06-04 2014-03-19 Ben Gurion University of the Negev Research and Development Authority Tri-aryl compounds and compositions comprising the same
US7858620B2 (en) 2007-09-19 2010-12-28 H. Lundbeck A/S Cyanoisoquinoline
TW200918519A (en) * 2007-09-19 2009-05-01 Lundbeck & Co As H Cyanoisoquinoline
TW200944523A (en) * 2008-02-08 2009-11-01 Organon Nv (Dihydro)pyrrolo[2,1-a]isoquinolines
CA2716788C (en) 2008-02-29 2016-08-16 Concert Pharmaceuticals, Inc. Deuterium-substituted xanthine derivatives
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
UA102693C2 (ru) * 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
TWI461426B (zh) * 2009-05-27 2014-11-21 Merck Sharp & Dohme （二氫）咪唑並異〔５，１－ａ〕喹啉類
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TW201200516A (en) 2009-12-17 2012-01-01 Lundbeck & Co As H Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors
TW201215607A (en) 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
TW201206935A (en) 2010-07-16 2012-02-16 Lundbeck & Co As H Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor
DE102010042833B4 (de) 2010-10-22 2018-11-08 Helmholtz-Zentrum Dresden - Rossendorf E.V. Neue Halogenalkoxychinazoline, deren Herstellung und Verwendung
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
WO2012112946A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2013045607A1 (en) 2011-09-30 2013-04-04 H. Lundbeck A/S Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors
WO2013050527A1 (en) 2011-10-05 2013-04-11 H. Lundbeck A/S Quinazoline derivatives as pde10a enzyme inhibitors
AR089361A1 (es) 2011-12-21 2014-08-20 Lundbeck & Co As H Derivados de quinolina como inhibidores de la enzima pde10a
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
CN103059029B (zh) * 2012-12-28 2014-12-10 塔里木大学 一种六氢吡咯[2,3]并吲哚类化合物及其制备方法和在杀菌活性中的应用
AU2013394970B2 (en) * 2013-07-25 2017-11-23 Centre National De La Recherche Scientifique Pyrroloquinoline derivatives as 5-HT6 antagonists, preparation method and use thereof
EA201690938A1 (ru) 2013-11-05 2016-11-30 Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити Соединения для лечения диабета и осложнений, возникающих из-за этого заболевания
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
CN106456647A (zh) 2014-04-18 2017-02-22 康塞特医药品有限公司 治疗高血糖症的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE690792A (zh) * 1966-12-07 1967-05-16
DE3401018A1 (de) * 1984-01-13 1985-07-18 Boehringer Ingelheim KG, 6507 Ingelheim Verfahren zur herstellung von 5,6-dihydro-pyrrolo(2,1-a)isochinolinen
FR2761358B1 (fr) * 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2002227985A1 (en) * 2000-12-13 2002-06-24 Bayer Aktiengesellschaft Pyrrolo (2.1-a) dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors
US20030018047A1 (en) * 2001-04-20 2003-01-23 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) * 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
DE10130151A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Neue Verwendung für PDE 10A-Inhibitoren
WO2003014115A1 (en) * 2001-08-06 2003-02-20 Bayer Aktiengesellschaft 3-substituted pyrrolo (2.1-a) isoquinoline derivatives
WO2003014116A1 (en) * 2001-08-06 2003-02-20 Bayer Corporation Pyrrolo[2.1-a]isoquinoline derivatives
AU2002366362A1 (en) * 2001-12-18 2003-06-30 Bayer Aktiengesellschaft 2-substituted pyrrolo(2.1-a)isoquinolines against cancer
WO2005003129A1 (en) * 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolodihydroisoquinolines as pde10 inhibitors
WO2006089815A1 (en) * 2005-01-12 2006-08-31 Nycomed Gmbh Novel pyrrolodihydroisoquinolines as pde10 inhibitors
JP2008526817A (ja) * 2005-01-12 2008-07-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のピロロジヒドロイソキノリン

Also Published As

Publication number Publication date
AU2004253690A1 (en) 2005-01-13
AU2004253694A1 (en) 2005-01-13
MXPA05013822A (es) 2006-02-28
NO20060202L (no) 2006-01-13
RS20050946A (en) 2008-06-05
WO2005003129A1 (en) 2005-01-13
DE602004028827D1 (de) 2010-10-07
EP1641794A1 (en) 2006-04-05
IL171997A0 (en) 2011-08-01
CA2530317A1 (en) 2005-01-13
EP1641792A1 (en) 2006-04-05
AR044956A1 (es) 2005-10-12
JP2009513494A (ja) 2009-04-02
WO2005003130A1 (en) 2005-01-13
RS20050945A (en) 2008-06-05
ZA200509267B (en) 2006-08-30
US20060148838A1 (en) 2006-07-06
EP1641792B1 (en) 2010-08-25
JP2009513495A (ja) 2009-04-02
UA86591C2 (ru) 2009-05-12
CA2530316A1 (en) 2005-01-13
KR20060030483A (ko) 2006-04-10
CN1809564A (zh) 2006-07-26
CN1809565A (zh) 2006-07-26
MXPA05013553A (es) 2006-03-09
US20060148840A1 (en) 2006-07-06
TW200510407A (en) 2005-03-16
ZA200509265B (en) 2006-10-25
AR045696A1 (es) 2005-11-09
ATE478868T1 (de) 2010-09-15
EA012110B1 (ru) 2009-08-28
AU2004253690B2 (en) 2010-03-25
BRPI0411897A (pt) 2006-08-29
IS8238A (is) 2006-01-18
EA200501928A1 (ru) 2006-12-29
NZ544591A (en) 2009-07-31

Similar Documents

Publication Publication Date Title
TW200510413A (en) Novel pyrrolodihydroisoquinolines
NL301145I1 (zh)
IL258880A (en) Compounds of diarylhydantoin
TW200612918A (en) Lonidamine analogs
NO20052922D0 (no) Fremgangsmate og sammensetninger for induksjon av apoptosis hos cancerceller
WO2004034990A3 (en) Methods and compositions for use in treating cancer
BRPI0611670A2 (pt) método para o tratamento ou prevenção de câncer em um indivíduo
DK1802625T3 (da) Disubstituerede pyrazolobenzodiazepiner der er nyttige som inhibitorer af CDK2 og angiogenese og til behandling af bryst-, tyktarms-, lunge- og prostatacancer
WO2004063355A3 (en) Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
WO2007061874A3 (en) Methods and compositions for use in treating cancer
PL1682530T3 (pl) Podstawione pirolo-indole jako inhibitory PAI-1
DK1261367T3 (da) Anvendelse af interleukin-6-antagonister til behandling af östrogenafhængige tumorer
ATE425982T1 (de) Thienopyrimidin-derivate als kaliumkanal- inhibitoren
WO2006075012A3 (en) Pyrrolodihydroisoquinolines as antiproliferative agents
ATE469659T1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
WO2003090680A3 (en) Novel phenyl derivatives as inducers of apoptosis
TW200605885A (en) Multicyclic lonidamine analogs
DK1757283T3 (da) Antitumorvirkningsforstærker, antitumor middel og fremgangsmåde til cancerterrapi
WO2005082357A8 (en) Use of beta-lapachone for treating hematologic tumors
WO2005086638A3 (en) Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof
ATE445408T1 (de) Verwendung von prolactin in der prophylaktischen krebstherapie
ATE435200T1 (de) Guanidinophenylalanin-verbindungen als urokinase- inhibitoren
MXPA03002494A (es) Metodo para reducir toxicidad de quimio terapias combinadas.
MX2022002607A (es) Metodos de tratamiento.
DE60232650D1 (de) Peptiddeformylaseinhibitoren